Sareum’s unusual spike
Don't get carried away by the 94% share price rally in Sareum (SAR:AIM) to 0.604p since the start of March 2016. The company hasn't been able to explain the sudden spike in its valuation, leaving us concerned that the shares may soon be subject to profit taking and fall back.The £15 million cap drug developer is expected to commence stage one clinical trials for lung and pancreatic cancer...